{"DataElement":{"publicId":"7028259","version":"1","preferredName":"Endometrial Carcinoma Hormone Therapy Agent Type","preferredDefinition":"Text term to identify a hormone therapy agent administered to an individual with endometrial cancer.","longName":"EDMTR_HORM_AGT_TYP","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"7024632","version":"1","preferredName":"Endometrial Carcinoma Hormone Therapy Agent","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation._Any agent that can alter hormone levels or modulate hormone effects.","longName":"3104218v1.0:7024630v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"3104218","version":"1","preferredName":"Endometrial Carcinoma","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation. -- 2004","longName":"C7558","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Carcinoma","conceptCode":"C7558","definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-07AC-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7024630","version":"1","preferredName":"Hormone Therapy Agent","preferredDefinition":"Any agent that can alter hormone levels or modulate hormone effects.","longName":"C147908","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy Agent","conceptCode":"C147908","definition":"Any agent that can alter hormone levels or modulate hormone effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9592CE54-BAF4-7E3A-E053-F662850A443D","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-23","modifiedBy":"ONEDATA","dateModified":"2019-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9592CE54-BB05-7E3A-E053-F662850A443D","latestVersionIndicator":"Yes","beginDate":"2019-10-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-23","modifiedBy":"HARTLEYG","dateModified":"2019-10-30","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2582816","version":"1.1","preferredName":"Hormone Therapy Agent Administered Type","preferredDefinition":"a chemical name for a hormonal compound given as treatment for cancer.","longName":"HORMONETX_AGT_ADM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Firmagon","valueDescription":"Degarelix","ValueMeaning":{"publicId":"3240855","version":"1","preferredName":"Degarelix","longName":"3240855","preferredDefinition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Degarelix","conceptCode":"C48385","definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4302120-6A24-B554-E040-BB89AD4307C7","latestVersionIndicator":"Yes","beginDate":"2011-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-26","modifiedBy":"COOPERM","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B26F-871B-E050-BB89AD435B24","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Degarelix acetate","valueDescription":"Degarelix Acetate","ValueMeaning":{"publicId":"5424692","version":"1","preferredName":"Degarelix Acetate","longName":"5424692","preferredDefinition":"The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Degarelix Acetate","conceptCode":"C80443","definition":"The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6CD4EC-B27C-871B-E050-BB89AD435B24","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B295-871B-E050-BB89AD435B24","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Nilutamide (Anandron)","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"2573402","version":"1","preferredName":"Nilutamide","longName":"2573402","preferredDefinition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B2A9-871B-E050-BB89AD435B24","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Anastrazole","valueDescription":"Anastrazole","ValueMeaning":{"publicId":"2921025","version":"1","preferredName":"Anastrazole","longName":"2921025","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CCEE-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BA2-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Buserelin","valueDescription":"Buserelin","ValueMeaning":{"publicId":"2576647","version":"1","preferredName":"Buserelin","longName":"2576647","preferredDefinition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buserelin","conceptCode":"C320","definition":"A synthetic analog of gonadotropin-releasing hormone (GnRH).  Buserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors.  Prolonged administration of buserelin results in sustained inhibition of gonadotropin production, suppression of testicular and ovarian steroidogenesis, and reduced levels of circulating gonadotropin and gonadal steroids. Buserelin is more potent that GnRH. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F874-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BAC-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Fulvestrant","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BB6-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Goserelin","valueDescription":"Goserelin","ValueMeaning":{"publicId":"2921026","version":"1","preferredName":"Goserelin","longName":"2921026","preferredDefinition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin","conceptCode":"C1374","definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD2F-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BC0-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Letrozole","valueDescription":"Letrozole","ValueMeaning":{"publicId":"2921027","version":"1","preferredName":"Letrozole","longName":"2921027","preferredDefinition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD52-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BCA-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Leuprolide","valueDescription":"Leuprolide","ValueMeaning":{"publicId":"2921029","version":"1","preferredName":"Leuprolide","longName":"2921029","preferredDefinition":"The active ingredient in a drug used to treat symptoms of advanced prostate cancer. It is also used to treat early puberty in children and certain gynecologic conditions. It is being studied in the treatment of other conditions and types of cancer. Leuprolide blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. It is a type of gonadotropin-releasing hormone analog.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leuprolide","conceptCode":"C62042","definition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2A9285-CD78-5F08-E040-BB89AD435BDA","latestVersionIndicator":"Yes","beginDate":"2009-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BD4-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"Tamoxifen","ValueMeaning":{"publicId":"2897675","version":"1","preferredName":"Tamoxifen","longName":"2897675","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB2B-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BDE-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Nilutamide","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"2573402","version":"1","preferredName":"Nilutamide","longName":"2573402","preferredDefinition":"A drug that blocks the effects of male hormones in the body. It is a type of antiandrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3BFC-6579-E050-BB89AD436442","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Ketoconazole","valueDescription":"Ketoconazole","ValueMeaning":{"publicId":"2578210","version":"1","preferredName":"Ketoconazole","longName":"2578210","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C06-6579-E050-BB89AD436442","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C10-6579-E050-BB89AD436442","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Aminoglutethimide","valueDescription":"Aminoglutethimide","ValueMeaning":{"publicId":"2576921","version":"1","preferredName":"Aminoglutethimide","longName":"2576921","preferredDefinition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglutethimide","conceptCode":"C233","definition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F986-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C1A-6579-E050-BB89AD436442","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Finasteride","valueDescription":"Finasteride","ValueMeaning":{"publicId":"2576856","version":"1","preferredName":"Finasteride","longName":"2576856","preferredDefinition":"A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F945-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C24-6579-E050-BB89AD436442","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Megestrol acetate","valueDescription":"Megestrol Acetate","ValueMeaning":{"publicId":"2580127","version":"1","preferredName":"Megestrol Acetate","longName":"2580127","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-060C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-06-28","modifiedBy":"ONEDATA","dateModified":"2006-06-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C2E-6579-E050-BB89AD436442","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Estrogen","valueDescription":"Estrogen","ValueMeaning":{"publicId":"2563598","version":"1","preferredName":"Estrogen","longName":"2563598","preferredDefinition":"A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen","conceptCode":"C2293","definition":"A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C57B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C38-6579-E050-BB89AD436442","beginDate":"2008-06-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Progestins","valueDescription":"Progestin","ValueMeaning":{"publicId":"2759898","version":"1","preferredName":"Progestin","longName":"2759898","preferredDefinition":"Any natural or laboratory-made substance that has some or all of the biologic effects of progesterone, a female hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progestin","conceptCode":"C776","definition":"Any synthetic steroid hormone that resembles the naturally occurring hormone and has progesterone-like properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FD39A5D-3B8B-4680-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-16","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-06-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C42-6579-E050-BB89AD436442","beginDate":"2008-06-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"DES","valueDescription":"Diethylstilbestrol","ValueMeaning":{"publicId":"2577843","version":"1","preferredName":"Diethylstilbestrol","longName":"2577843","preferredDefinition":"DES; the acronym for diethylstilbestrol, a synthetic, nonsteroidal form of estrogen.  A well-known teratogen and carcinogen, DES inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diethylstilbestrol","conceptCode":"C433","definition":"A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD20-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C4C-6579-E050-BB89AD436442","beginDate":"2008-06-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"3030997","version":"1","preferredName":"None","longName":"3030997","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82DD865C-2FEA-9DF4-E040-BB89AD434EAA","latestVersionIndicator":"Yes","beginDate":"2010-03-28","endDate":null,"createdBy":"CURTIST","dateCreated":"2010-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C56-6579-E050-BB89AD436442","beginDate":"2010-05-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Other specify","ValueMeaning":{"publicId":"2570538","version":"1","preferredName":"Other specify","longName":"2570538","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E097-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2023-11-17","changeDescription":"Associated concept to VM for TCGA. mc 11/9/12 - reversed concept order to match the semantics of this phrase which is \"other\" with \"specify\" as a qualifier/modifier - DW 12-30-2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C60-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Triptorelin Acetate","valueDescription":"Triptorelin Acetate","ValueMeaning":{"publicId":"4111915","version":"1","preferredName":"Triptorelin Acetate","longName":"4111915","preferredDefinition":"Triptorelin Acetate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0A6CACD-14E4-467D-E040-BB89AD432147","latestVersionIndicator":"Yes","beginDate":"2014-01-23","endDate":null,"createdBy":"BASSG","dateCreated":"2014-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C6A-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Toremifene Citrate","valueDescription":"Toremifene Citrate","ValueMeaning":{"publicId":"4111916","version":"1","preferredName":"Toremifene Citrate","longName":"4111916","preferredDefinition":"The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toremifene Citrate","conceptCode":"C1756","definition":"The citrate salt of a nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which is manifested depending on the tissue or species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0A6CACD-1511-467D-E040-BB89AD432147","latestVersionIndicator":"Yes","beginDate":"2014-01-23","endDate":null,"createdBy":"BASSG","dateCreated":"2014-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C7E-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Raloxifene","valueDescription":"Raloxifene","ValueMeaning":{"publicId":"2561707","version":"1","preferredName":"Raloxifene","longName":"2561707","preferredDefinition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raloxifene","conceptCode":"C1518","definition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE18-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C88-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Megestrol","valueDescription":"Megestrol","ValueMeaning":{"publicId":"2576649","version":"1","preferredName":"Megestrol","longName":"2576649","preferredDefinition":"A synthetic derivative of progesterone with antiestrogenic activity.  Megestrol binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. In addition, megestrol stimulates the appetite in cachectic subjects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol","conceptCode":"C630","definition":"A synthetic derivative of progesterone with antiestrogenic activity. Megestrol binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. In addition, megestrol stimulates appetite in cachectic subjects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C92-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Medroxyprogesterone","valueDescription":"Medroxyprogesterone","ValueMeaning":{"publicId":"2578261","version":"1","preferredName":"Medroxyprogesterone","longName":"2578261","preferredDefinition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medroxyprogesterone","conceptCode":"C629","definition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3C9C-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"LHRH Agonist","valueDescription":"LHRH agonist","ValueMeaning":{"publicId":"2573099","version":"1","preferredName":"LHRH agonist","longName":"2573099","preferredDefinition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotropin-releasing Hormone Analog","conceptCode":"C1910","definition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-08","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3CA6-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Gonadotropin-Releasing Hormone","valueDescription":"Gonadotropin-Releasing Hormone","ValueMeaning":{"publicId":"4111918","version":"1","preferredName":"Gonadotropin-Releasing Hormone","longName":"4111918","preferredDefinition":"A hormone made by the hypothalamus (part of the brain). GnRH causes the pituitary gland to make luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones are involved in reproduction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotrophin Releasing Hormone","conceptCode":"C2270","definition":"Specifically expressed in hypothalamic neurons as a preproprotein, Gonadotropin Releasing Hormones (GnRH Family) are secreted into the median eminence capillary plexus, bind to receptors on anterior pituitary gonadotrophs, and stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to control female reproduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F0A6CACD-157F-467D-E040-BB89AD432147","latestVersionIndicator":"Yes","beginDate":"2014-01-23","endDate":null,"createdBy":"BASSG","dateCreated":"2014-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3CBA-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Diethylstilbestrol","valueDescription":"Diethylstilbestrol","ValueMeaning":{"publicId":"2577843","version":"1","preferredName":"Diethylstilbestrol","longName":"2577843","preferredDefinition":"DES; the acronym for diethylstilbestrol, a synthetic, nonsteroidal form of estrogen.  A well-known teratogen and carcinogen, DES inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diethylstilbestrol","conceptCode":"C433","definition":"A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD20-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3CD8-6579-E050-BB89AD436442","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Exemestane","valueDescription":"Exemestane","ValueMeaning":{"publicId":"2563643","version":"1","preferredName":"Exemestane","longName":"2563643","preferredDefinition":"A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exemestane","conceptCode":"C1097","definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5A8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3CEC-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Toremifene","valueDescription":"Toremifene","ValueMeaning":{"publicId":"2563593","version":"1","preferredName":"Toremifene","longName":"2563593","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiestrogens. Toremifene blocks the effect of the hormone estrogen in the body. It may help control some cancers from growing, and it may delay or reduce the risk of cancer recurrence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toremifene","conceptCode":"C1256","definition":"A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C576-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF77A-3CF6-6579-E050-BB89AD436442","beginDate":"2009-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Abiraterone Acetate (Zytiga)","valueDescription":"Abiraterone Acetate","ValueMeaning":{"publicId":"5425971","version":"1","preferredName":"Abiraterone Acetate","longName":"5425971","preferredDefinition":"An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone Acetate","conceptCode":"C68845","definition":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A714DC5-A5C1-9607-E050-BB89AD43167A","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"GDEEN","dateModified":"2022-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A714DC5-A5DA-9607-E050-BB89AD43167A","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Flutamide (Eulexin)","valueDescription":"Flutamide","ValueMeaning":{"publicId":"3379052","version":"1","preferredName":"Flutamide","longName":"3379052","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914931D-212B-28A3-E040-BB89AD437288","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A5AF4CE-1413-CBB2-E050-BB89AD4348E7","beginDate":"2016-08-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"ONEDATA","dateModified":"2016-08-18","deletedIndicator":"No"},{"value":"Enzalutamide (Xtandi_MDV3100)","valueDescription":"Enzalutamide","ValueMeaning":{"publicId":"5424693","version":"1","preferredName":"Enzalutamide","longName":"5424693","preferredDefinition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6CD4EC-B2B3-871B-E050-BB89AD435B24","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B2CC-871B-E050-BB89AD435B24","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Goserelin acetate (Zoladex)","valueDescription":"Goserelin Acetate","ValueMeaning":{"publicId":"3380783","version":"1","preferredName":"Goserelin Acetate","longName":"3380783","preferredDefinition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin Acetate","conceptCode":"C1417","definition":"The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5B54-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B2E0-871B-E050-BB89AD435B24","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Leuprolide acetate (Lupron_Eligard_Viadur_Vantas)","valueDescription":"Leuprolide Acetate","ValueMeaning":{"publicId":"2576645","version":"1","preferredName":"Leuprolide Acetate","longName":"2576645","preferredDefinition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leuprolide Acetate","conceptCode":"C1319","definition":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F872-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B2F4-871B-E050-BB89AD435B24","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Bicalutamide (Casodex)","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B2FE-871B-E050-BB89AD435B24","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Ethinyl Estradiol","valueDescription":"Ethinyl Estradiol","ValueMeaning":{"publicId":"2576830","version":"1","preferredName":"Ethinyl Estradiol","longName":"2576830","preferredDefinition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol","conceptCode":"C486","definition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B308-871B-E050-BB89AD435B24","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Triptorelin (Trelstar)","valueDescription":"Triptorelin","ValueMeaning":{"publicId":"3380222","version":"1","preferredName":"Triptorelin","longName":"3380222","preferredDefinition":"A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin","conceptCode":"C1267","definition":"A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1517-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A6CD4EC-B31C-871B-E050-BB89AD435B24","beginDate":"2014-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"ONEDATA","dateModified":"2016-08-19","deletedIndicator":"No"},{"value":"Histrelin","valueDescription":"Histrelin Acetate","ValueMeaning":{"publicId":"5989730","version":"1","preferredName":"Histrelin Acetate","longName":"5989730","preferredDefinition":"The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histrelin Acetate","conceptCode":"C77424","definition":"The acetate salt form of histrelin, a long-acting, synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) with potential anti-tumor activity. Upon administration, histrelin binds to and activates GnRH receptors; prolonged administration results in pituitary GnRH receptor desensitization and inhibition of follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion, leading to a significant decline in testosterone production in males and may inhibit androgen receptor-positive tumor progression; in females, prolonged administration results in decreased estradiol production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD1DD71-A017-6B8B-E053-F662850A351F","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5AD1DD71-A030-6B8B-E053-F662850A351F","beginDate":"2017-10-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-05","modifiedBy":"ONEDATA","dateModified":"2017-10-05","deletedIndicator":"No"},{"value":"CDK4/6 inhibitor","valueDescription":"CDK4/6 Inhibitor SHR6390","ValueMeaning":{"publicId":"6066733","version":"1","preferredName":"CDK4/6 Inhibitor SHR6390","longName":"6066733","preferredDefinition":"A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, CDK4/6 inhibitor SHR6390 selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dalpiciclib","conceptCode":"C125899","definition":"A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"64CC59FA-DEDC-6D3C-E053-F662850A7E69","latestVersionIndicator":"Yes","beginDate":"2018-02-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-09","modifiedBy":"ONEDATA","dateModified":"2018-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"64CC59FA-DEF5-6D3C-E053-F662850A7E69","beginDate":"2018-02-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-09","modifiedBy":"ONEDATA","dateModified":"2018-02-09","deletedIndicator":"No"},{"value":"Lanreotide","valueDescription":"Lanreotide","ValueMeaning":{"publicId":"3379573","version":"1","preferredName":"Lanreotide","longName":"3379573","preferredDefinition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lanreotide","conceptCode":"C1523","definition":"A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-37B4-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D0CA-65C0-E053-F662850AF3F1","beginDate":"2018-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Octreotide","valueDescription":"Octreotide","ValueMeaning":{"publicId":"3379281","version":"1","preferredName":"Octreotide","longName":"3379281","preferredDefinition":"The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Octreotide","conceptCode":"C711","definition":"A synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C655-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D0D4-65C0-E053-F662850AF3F1","beginDate":"2018-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Androgen deprivation (specify)","valueDescription":"Androgen Suppression","ValueMeaning":{"publicId":"5629239","version":"1","preferredName":"Androgen Suppression","longName":"5629239","preferredDefinition":"Treatment to suppress or block the production or action of male hormones. This is done by having the testicles removed, by taking female sex hormones, or by taking drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Androgen Suppression","conceptCode":"C15676","definition":"Blockage of the production of male hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46622A36-825D-65A1-E053-F662850A9323","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-18","modifiedBy":"COLBERTM","dateModified":"2023-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ABE70CA-490E-4271-E053-F662850A525B","beginDate":"2019-06-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-07","modifiedBy":"ONEDATA","dateModified":"2019-06-07","deletedIndicator":"No"},{"value":"Herceptin","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ABE70CA-4919-4271-E053-F662850A525B","beginDate":"2019-06-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-07","modifiedBy":"ONEDATA","dateModified":"2019-06-07","deletedIndicator":"No"},{"value":"Itraconazole","valueDescription":"Itraconazole","ValueMeaning":{"publicId":"2578206","version":"1","preferredName":"Itraconazole","longName":"2578206","preferredDefinition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Itraconazole","conceptCode":"C1138","definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE19A6F-2C9E-10C0-E053-F662850A193E","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Darolutamide","valueDescription":"AR Antagonist ODM-201","ValueMeaning":{"publicId":"6159883","version":"1","preferredName":"Darolutamide","longName":"6159883v1.00","preferredDefinition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darolutamide","conceptCode":"C104748","definition":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A540C7-4B98-0CA2-E053-F662850A07D0","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"KUMMEROA","dateModified":"2022-08-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE19A6F-2CB2-10C0-E053-F662850A193E","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Apalutamide","valueDescription":"Apalutamide","ValueMeaning":{"publicId":"5811375","version":"1","preferredName":"Apalutamide","longName":"5811375","preferredDefinition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apalutamide","conceptCode":"C92574","definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F2E845A-26D5-6A9B-E053-F662850ACCDA","latestVersionIndicator":"Yes","beginDate":"2017-05-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE19A6F-2CC6-10C0-E053-F662850A193E","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Orteronel","valueDescription":"Steroid 17alpha-monooxygenase TAK-700","ValueMeaning":{"publicId":"3259298","version":"1","preferredName":"Steroid 17alpha-monooxygenase TAK-700","longName":"3259298","preferredDefinition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orteronel","conceptCode":"C90582","definition":"An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity. TAK-700 binds to and inhibits the steroid 17alpha-monooxygenase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1 (P450C17), localized to the endoplasmic reticulum (ER), exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones, such as progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A939DA44-CB85-3822-E040-BB89AD432672","latestVersionIndicator":"Yes","beginDate":"2011-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE19A6F-2CD0-10C0-E053-F662850A193E","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Progestational IUD","valueDescription":"Progestogen Intrauterine Device","ValueMeaning":{"publicId":"7029162","version":"1","preferredName":"Progestogen Intrauterine Device","longName":"7029162","preferredDefinition":"Substances that produce effects similar to those of progesterone, the only natural progestogen. All other progestogens are synthetic and are often referred to as progestins. All progestogens have antiestrogenic and antigonadotropic properties.: A device usually made of plastic or metal, inserted into the uterus to prevent conception. IUCD can be a coil, loop, triangle, or T in shape; its material can be impregnated with a pharmaceutical agent. The primary action of all IUCDs is the induction of a foreign-body reaction within the endometrium. This sterile inflammatory process is toxic to gametes, primarily spermatozoa, and effectively prevents viable sperm from passing into the fallopian tubes. The copper-bearing device has an independent toxic effect on spermatozoa. The progestin-releasing devices produce changes in endometrial architecture and function that reduce the potential for implantation of a fertilized egg. The progestin effect on the cervical mucus also reduces the penetrability of sperm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progestogen","conceptCode":"C2296","definition":"Substances that produce effects similar to those of progesterone, the only natural progestogen. All other progestogens are synthetic and are often referred to as progestins. All progestogens have antiestrogenic and antigonadotropic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intrauterine Device","conceptCode":"C42771","definition":"A device usually made of plastic or metal, inserted into the uterus to prevent conception. IUCD can be a coil, loop, triangle, or T in shape; its material can be impregnated with a pharmaceutical agent. The primary action of all IUCDs is the induction of a foreign-body reaction within the endometrium. This sterile inflammatory process is toxic to gametes, primarily spermatozoa, and effectively prevents viable sperm from passing into the fallopian tubes. The copper-bearing device has an independent toxic effect on spermatozoa. The progestin-releasing devices produce changes in endometrial architecture and function that reduce the potential for implantation of a fertilized egg. The progestin effect on the cervical mucus also reduces the penetrability of sperm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95FB4DC4-BD51-5679-E053-F662850A7285","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-28","modifiedBy":"ONEDATA","dateModified":"2019-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95FB4DC4-BD6A-5679-E053-F662850A7285","beginDate":"2019-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-28","modifiedBy":"ONEDATA","dateModified":"2019-10-28","deletedIndicator":"No"},{"value":"Gonadotropin-releasing hormone (GnRH) agonists","valueDescription":"Agonist Gonadotrophin Releasing Hormone","ValueMeaning":{"publicId":"7409919","version":"1","preferredName":"Agonist Gonadotrophin Releasing Hormone","longName":"7409919","preferredDefinition":"An agent that has affinity for a receptor and intrinsic activity at that receptor.: A hormone made by the hypothalamus (part of the brain). GnRH causes the pituitary gland to make luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones are involved in reproduction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agonist","conceptCode":"C1514","definition":"An agent that has affinity for a receptor and intrinsic activity at that receptor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gonadotrophin Releasing Hormone","conceptCode":"C2270","definition":"Specifically expressed in hypothalamic neurons as a preproprotein, Gonadotropin Releasing Hormones (GnRH Family) are secreted into the median eminence capillary plexus, bind to receptors on anterior pituitary gonadotrophs, and stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to control female reproduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADF4748F-2C28-7D66-E053-4EBD850A76C1","latestVersionIndicator":"Yes","beginDate":"2020-08-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-28","modifiedBy":"ONEDATA","dateModified":"2020-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADF4748F-2C41-7D66-E053-4EBD850A76C1","beginDate":"2020-08-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-28","modifiedBy":"ONEDATA","dateModified":"2020-08-28","deletedIndicator":"No"},{"value":"Progesterone","valueDescription":"PROGESTERONE","ValueMeaning":{"publicId":"2563599","version":"1","preferredName":"PROGESTERONE","longName":"2563599","preferredDefinition":"Produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone","conceptCode":"C2297","definition":"Produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADF4748F-2C4B-7D66-E053-4EBD850A76C1","beginDate":"2020-08-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-28","modifiedBy":"ONEDATA","dateModified":"2020-08-28","deletedIndicator":"No"},{"value":"Testosterone","valueDescription":"Testosterone","ValueMeaning":{"publicId":"2579543","version":"1","preferredName":"Testosterone","longName":"2579543","preferredDefinition":"(tes-TOS-ter-own) A hormone that promotes the development and maintenance of male sex characteristics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-03C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-06-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ADF4748F-2C55-7D66-E053-4EBD850A76C1","beginDate":"2020-08-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-08-28","modifiedBy":"ONEDATA","dateModified":"2020-08-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A5AF77A-3B82-6579-E050-BB89AD436442","latestVersionIndicator":"Yes","beginDate":"2006-12-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-18","modifiedBy":"CAMPBELB","dateModified":"2020-08-28","changeDescription":"Versioned to remove redundant PVs, add PVs and add concepts to VMs. mc 8/18/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"7026248","version":"1","longName":"Endometrial","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Hormone therapy","type":"Preferred Question Text","description":"Hormone therapy","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95C30374-3953-3F78-E053-F662850AEA18","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-25","modifiedBy":"HARTLEYG","dateModified":"2019-11-07","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}